Japan's Esai to Use Chinese Amoy Gene Tests to Develop Bile Duct Cancer Drug
Tang Shihua
DATE:  Nov 25 2019
/ SOURCE:  yicai
Japan's Esai to Use Chinese Amoy Gene Tests to Develop Bile Duct Cancer Drug Japan's Esai to Use Chinese Amoy Gene Tests to Develop Bile Duct Cancer Drug

(Yicai Global) Nov. 25 -- Japanese pharmaceutical giant Esai will use gene testing products independently developed by China's Amoy Diagnostics in China and Japan to seek ways to find cures to a rare form of cancer that develops in bile ducts.

Amoy and Esai penned a cooperation agreement regarding the use of the reagent for cholangiocarcinoma research, the Xiamen-based maker of kits to detect genetic mutation said in a statement on Nov. 22, without disclosing financial details. 

Before this, Amoy's diagnostic technologies have been used by global firms such as Loxo Oncology, a unit of Eli Lilly, and US Pfizer to develop cancer drugs in Asia. The company has obtained approvals to sell its products in Japan and South Korea. 

Amoy's [SHE: 300685] stock price rose by 0.6 percent to CNY71.90 (USD10.20) this morning. Its shares have nearly doubled in value this year.  

Editor: Emmi Laine

Follow Yicai Global on
Keywords:   Clinical Trial,New Medicine,Esai